证券代码：600774 股票简称：汉商集团 编号：2023-025 二、补贴的类型及其对公司的影响 上述共计获得与收益相关的政府补贴金额为人民币 16,758,065.15 元，公司 将根据《企业会计准则 16 号--政府补助》的相关规定对上述事项予以确认和计 量，具体会计处理须以会计师年度审计确认后的结果为准，敬请广大投资者注意 投资风险。 特此公告。 汉商集团股份有限公司 关于获得政府补贴的公告 汉商集团股份有限公司（以下简称"公司"）及所属企业在 2022 年 12 月 29 日至本公告发布日期间，收到政府补贴共计 16,758,065.15 元，占公司最近一期 经审计归属于上市公司股东净利润的 18.94%。现将补贴情况公告如下： | | | | | | 币种：人民币 | 单位：元 | | --- | --- | --- | --- | --- | --- | --- | | 序 | | | | | 补 贴 | | | 号 | 收款单位 | 项目内容 | 获得时间 | 补贴金额 | 类 | 补贴依据 | | | | | | | 型 | | | | 成都迪康 中科生物 | 创新医疗器 | | | 收益 ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,386,976,174.51, a decrease of 5.98% compared to CNY 1,475,250,374.49 in 2021[22] - The net profit attributable to shareholders of the listed company was CNY 88,484,898.33, an increase of 3.27% from CNY 85,679,135.85 in the previous year[22] - The net profit after deducting non-recurring gains and losses was CNY 42,851,268.58, a decrease of 22.42% compared to CNY 55,235,107.87 in 2021[22] - The net cash flow from operating activities was CNY 242,346,281.77, down 27.22% from CNY 332,997,567.15 in the previous year[22] - The total assets at the end of 2022 were CNY 3,497,888,940.62, an increase of 7.62% from CNY 3,250,183,574.06 at the end of 2021[22] - The net assets attributable to shareholders of the listed company were CNY 1,665,546,780.00, a slight increase of 1.13% from CNY 1,647,013,976.29 in 2021[22] - Basic earnings per share for 2022 were CNY 0.2999, a decrease of 13.62% from CNY 0.3472 in 2021[23] - The weighted average return on net assets was 5.37%, down 3.49 percentage points from 8.86% in the previous year[23] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of CNY 0.60 per 10 shares, with no stock bonus or capital increase[6] - The total cash dividend amount for the reporting period is approximately 57.47 million RMB, which represents 64.95% of the net profit attributable to ordinary shareholders[173] Business Operations and Strategy - The company is transitioning the Wuhan Tongji Reproductive Medicine Hospital to a for-profit entity, aiming to enhance its market competitiveness[32] - The company is implementing a business transformation strategy in its exhibition sector, focusing on upgrading traditional commerce and enhancing operational efficiency[33] - The company’s strategic focus includes expanding its presence in the health and commercial sectors, particularly in traditional Chinese medicine and assisted reproduction[29] - The company is expanding its OTC sales team to enhance market share across various provinces in China[44] - The company aims to increase the scale of self-organized exhibitions to improve the gross profit margin of its exhibition business[54] - The company is committed to enhancing R&D intensity to meet clinical needs and improve drug innovation[95] Research and Development - Research and development expenses increased by 11.15% to CNY 54,506,408.84, driven by the initiation of clinical trials for innovative drug projects[63] - The company reported a significant decrease in R&D investment for the drug "Rabeprazole," with a 36.83% decline compared to the previous year[117] - The company has 83 R&D personnel, accounting for 6% of total employees[78] - The company’s total R&D investment for the reporting period was CNY 57.01 million, with CNY 49.32 million in expense-based R&D and CNY 7.69 million in capitalized R&D, resulting in a capitalized R&D ratio of 13.50%[115] Market and Industry Trends - The pharmaceutical manufacturing industry in China saw a revenue of CNY 2,911.14 billion, a year-on-year decrease of 1.6%[34] - The total profit for the pharmaceutical manufacturing industry in 2022 was CNY 428.87 billion, down 31.8% year-on-year[34] - The medical device industry in China is projected to reach a revenue of CNY 1.3 trillion in 2022, with an estimated growth rate of around 12%[36] - The pharmaceutical manufacturing industry is expected to recover rapidly in 2023, driven by supportive national policies[93] Environmental and Social Responsibility - The company invested 1.6 million RMB in environmental protection during the reporting period[177] - The company has implemented a comprehensive environmental management system, enhancing awareness and compliance among all employees[184] - The company has established an emergency response plan for environmental incidents, which was approved and filed with the local environmental authority[182] - The company was recognized as a "Good Environmental Protection Enterprise" in Sichuan Province in 2022, reflecting its commitment to environmental management and compliance[187] Governance and Management - The company has established a governance structure that complies with legal requirements, ensuring equal rights for all shareholders, particularly minority shareholders[144] - The board of directors consists of 9 members, including 3 independent directors, and has established various committees to enhance governance and oversight[145] - The company has implemented a performance evaluation and incentive mechanism to ensure transparency and fairness in its operations[145] - The company emphasizes a combination of salary management and performance evaluation standards for determining remuneration[155] Risks and Challenges - The company acknowledges significant risks from industry policies affecting the pharmaceutical and medical device sectors, including dynamic adjustments to the drug procurement catalog and price controls, which may impact production costs and profitability[139] - The company faces high risks in new drug and medical device development due to high costs, long cycles, and low success rates, and plans to implement risk management strategies to improve success rates[140] - The trend of drug price reductions in China is expected to continue, which may force the company to lower prices due to collective procurement and negotiations, prompting a focus on production efficiency and innovation[141]

2023 年第一季度报告 证券代码：600774 证券简称：汉商集团 汉商集团股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度(%) | | | --- | --- | --- | --- | | 营业收入 | 361,417,097.31 | | 1.16 | | 归属于上市公司股东的净利润 | 24,256,576.86 | | 4.29 | | 归属于上市公司股东的扣除非经常 | 23,178,067.53 | | 8.27 | | 性损益的净 ...

会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 26 日(星期三) 至 05 月 05 日(星期五)16:00 前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 hshsd@126.com 进行提问。公司 将在说明会上对投资者普遍关注的问题进行回答。 汉商集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日披露公 司 2022 年年度报告。为了便于广大投资者更全面深入地了解本公司 2022 年年度 经营成果、财务状况，公司计划于 2023 年 05 月 08 日 下午 15:00-16:00 举行 2022 年度暨 2023 年第一季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 证券代码：600774 股票简称：汉商集团 编号：2023-015 汉商集团股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚 ...

2022 年第三季度报告 证券代码：600774 证券简称：汉商集团 汉商集团股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2022 年第三季度报告 | | 本报告期末 | 上年度末 | 本报告期末比上 年度末增减变动 | | --- | --- | --- | --- | | | | | 幅度(%) | | 总资产 | 3,380,810,022.00 | 3,250,183,574.06 | 4.02 | | 归属于上市公司 | | | | | 股东的所有者权 | 1,643,267,463.83 | 1,647,013,976.29 | -0.23 | | 益 | | | | 注:"本报告期"指本季度初至本季度末 3 个月期间，下同。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中 财务 ...

Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 700.90 million, a decrease of 5.06% compared to CNY 738.29 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2022 was CNY 42.64 million, representing a slight increase of 1.51% from CNY 42.00 million in the previous year[18]. - The basic earnings per share for the first half of 2022 was CNY 0.1445, down 21.93% from CNY 0.1851 in the same period last year[18]. - The weighted average return on net assets decreased to 2.56%, down 3.59 percentage points from 6.15% in the previous year[18]. - The net cash flow from operating activities was CNY 76.76 million, a significant decrease of 36.54% compared to CNY 120.95 million in the same period last year[18]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was CNY 38.48 million, down 3.64% from CNY 39.94 million in the previous year[18]. - The company achieved operating revenue of CNY 700.90 million in the first half of 2022, a decrease of 5.06% compared to the same period last year[33]. - The net profit attributable to shareholders was CNY 42.64 million, an increase of 1.51% year-on-year[33]. - The company reported a significant increase in long-term borrowings to CNY 290,000,000.00 from CNY 69,790,000.00, representing a growth of approximately 315.5%[102]. - The total profit for the first half of 2022 was RMB 43,853,987.42, a decrease of 15.6% from RMB 51,953,967.38 in the same period last year[104]. Business Strategy and Operations - The company continues to focus on the dual business strategy of "big health + big commerce," with its main businesses being pharmaceuticals, medical devices, and commercial operations[20]. - The pharmaceutical segment includes 80 types of drugs, with core products targeting digestive and respiratory systems, including new generation proton pump inhibitors[21]. - The company has established a sales network covering over 31 provinces, with a self-operated sales team of more than 400 people, achieving product coverage in over 10,000 hospitals[30]. - The medical device business focuses on absorbable biomedical materials, with products like absorbable medical membranes and screws, which are competitive in various surgical fields[24]. - The company is actively expanding its product pipeline in the medical device sector, aiming for breakthroughs in technology and patent reserves[25]. - The company is pursuing a strategy of internal cultivation and external acquisitions to enhance its pharmaceutical retail channel coverage[33]. - The company is restructuring its commercial projects to maximize operational efficiency, focusing on creating a digital and experiential shopping environment[37]. Research and Development - The company has increased R&D expenses by 24.23% to CNY 18.71 million, reflecting a focus on enhancing its product development capabilities[38]. - The company has completed Phase I clinical trials for its global Class I innovative drug DDCI-01 and is initiating Phase II trials for pulmonary arterial hypertension (PAH)[31]. - R&D efforts are focused on both innovative and generic drugs, with an emphasis on managing various risks throughout the development process[47]. - The company capitalizes R&D expenses for new drug development starting from the Phase II clinical trial stage[200]. Financial Position and Assets - The total assets at the end of the reporting period increased by 6.68% to CNY 3.47 billion from CNY 3.25 billion at the end of the previous year[18]. - Cash and cash equivalents increased by 79.18% to ¥487,740,269.85, representing 14.07% of total assets[40]. - The company reported a total of 79,444,603 shares held by Wuhan Hanyang Investment Development Group, the largest unrestricted shareholder[88]. - The company's total liabilities reached CNY 1,691,560,952.93, compared to CNY 1,456,810,918.56, which is an increase of approximately 16.1%[98]. - The total current assets rose to CNY 771,295,013.11 from CNY 611,654,666.66, indicating an increase of about 26.1%[100]. Environmental Management - The company has established a comprehensive environmental management system, significantly enhancing employee awareness of environmental protection[64]. - The company has received the "Environmental Good Enterprise" title in Sichuan Province for two consecutive years[65]. - The company has established an emergency response plan for environmental incidents, which was approved and filed with the local environmental authority[60]. - The wastewater treatment process at Dikang Changjiang includes multiple stages and complies with relevant environmental regulations[58]. Risk Management - The company has not identified any significant risks affecting its ongoing operations during the reporting period[6]. - The company faces risks related to policy changes in the pharmaceutical industry, which could impact operational costs and compliance[46]. - The company is actively managing risks associated with price reductions due to centralized procurement policies, which could affect revenue and profit margins[47]. - The ongoing COVID-19 pandemic presents uncertainties that could impact business operations and consumer demand, necessitating effective cost control measures[48]. Corporate Governance - The company elected five non-independent directors and three independent directors to the board during the 2022 annual general meeting[50]. - The company reported no profit distribution or capital reserve increase plan for the first half of 2022[53]. - There are no changes in the controlling shareholder or actual controller during the reporting period[92]. Accounting and Financial Reporting - The financial statements are prepared based on the assumption of going concern, following the relevant accounting standards and regulations[137]. - The company adheres to the accounting policies that ensure the financial statements reflect a true and complete view of its financial position and performance[138]. - The group determines the scope of consolidated financial statements based on control, which includes the company and all subsidiaries[146]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired in a business combination[143].

Financial Performance - The company's operating revenue for Q1 2022 was ¥357,286,603.21, representing a decrease of 3.02% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥23,258,554.56, an increase of 4.13% year-over-year[3]. - Total revenue for Q1 2022 was CNY 357.29 million, a decrease of 3.03% from CNY 368.40 million in Q1 2021[18]. - Operating profit for Q1 2022 was CNY 22.81 million, compared to CNY 28.11 million in Q1 2021, reflecting a decline of 18.93%[18]. - Net profit for Q1 2022 was CNY 16.51 million, down from CNY 20.11 million in Q1 2021, a decrease of 17.73%[18]. - Net profit for Q1 2022 was ¥16,513,662.17, a decrease of 18.0% compared to ¥20,113,177.22 in Q1 2021[19]. - Revenue from sales of goods and services in Q1 2022 was ¥489,458,093.51, down 19.7% from ¥609,462,096.53 in Q1 2021[22]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥7,030,251.48, a significant decrease of 118.9% compared to the previous year[3]. - Operating cash flow for Q1 2022 showed a net outflow of ¥7,030,251.48, contrasting with a net inflow of ¥37,189,788.78 in Q1 2021[22]. - Cash and cash equivalents increased to CNY 399.45 million as of March 31, 2022, up from CNY 272.21 million at the end of 2021, representing a growth of 46.81%[12]. - Cash and cash equivalents at the end of Q1 2022 increased to ¥456,648,230.29 from ¥148,393,584.61 at the end of Q1 2021, marking a significant improvement[23]. - The company reported a net cash inflow from financing activities of ¥139,778,363.46 in Q1 2022, compared to a net outflow of ¥212,953,231.33 in Q1 2021[23]. - Cash flow from investment activities showed a net outflow of ¥5,501,012.35 in Q1 2022, compared to a net outflow of ¥5,244,103.50 in Q1 2021[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,389,872,276.14, an increase of 4.30% from the end of the previous year[3]. - Total assets as of March 31, 2022, amounted to ¥2,481,045,568.01, an increase from ¥2,374,921,744.36 at the end of 2021[26]. - Total liabilities increased to CNY 1.58 billion as of March 31, 2022, compared to CNY 1.46 billion at the end of 2021, an increase of 8.51%[14]. - Total liabilities as of March 31, 2022, amounted to CNY 977,341,271.28, an increase from CNY 872,481,850.63 at the end of 2021[27]. - Short-term borrowings increased to CNY 233,308,095.89 from CNY 208,297,249.21 at the end of 2021[27]. - Long-term borrowings rose significantly to CNY 278,530,000.00 from CNY 69,790,000.00 at the end of 2021[27]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,242[6]. - The top shareholder, Wuhan Hanyang Investment Development Group Co., Ltd., held 26.93% of the shares[8]. - Shareholders' equity rose to CNY 1.81 billion as of March 31, 2022, compared to CNY 1.79 billion at the end of 2021, reflecting an increase of 0.86%[14]. - Total equity as of March 31, 2022, was CNY 1,503,704,296.73, slightly up from CNY 1,502,439,893.73 at the end of 2021[27]. Expenses - Research and development expenses increased by 58.44%, primarily due to increased R&D spending by the subsidiary Dikon Pharmaceutical[5]. - The company reported a decrease in sales expenses to CNY 9,542,512.19 from CNY 8,171,166.21 in Q1 2021[28]. - Financial expenses decreased significantly to CNY 5,418,457.83 from CNY 11,081,500.83 in Q1 2021, with interest expenses dropping to CNY 8,562,826.72 from CNY 14,056,064.22[28]. Earnings Per Share - Basic earnings per share decreased by ¥0.0237 to ¥0.0788[3]. - Basic and diluted earnings per share for Q1 2022 were both ¥0.0788, down from ¥0.0984 in Q1 2021, reflecting a decline of 20.0%[19]. - The weighted average return on equity decreased by 2.03 percentage points to 1.29%[3].

Financial Performance - The company's operating revenue for 2021 was RMB 1,475,250,374.49, representing a 197.91% increase compared to RMB 495,200,411.33 in 2020[21] - The net profit attributable to shareholders for 2021 was RMB 85,679,135.85, an increase of 88.36% from RMB 45,486,168.42 in 2020[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 55,235,107.87, compared to a loss of RMB 30,403,093.74 in 2020[21] - The net cash flow from operating activities for 2021 was RMB 332,997,567.15, a significant increase of 535.75% from RMB 52,378,354.04 in 2020[21] - The total assets at the end of 2021 were RMB 3,250,183,574.06, slightly up by 0.08% from RMB 3,247,673,152.04 at the end of 2020[21] - The net assets attributable to shareholders increased by 148.62% to RMB 1,647,013,976.29 from RMB 662,462,196.77 in 2020[21] - The basic earnings per share for 2021 were RMB 0.3472, a 73.25% increase from RMB 0.2004 in 2020[22] - The weighted average return on net assets for 2021 was 8.86%, an increase of 1.79 percentage points from 7.07% in 2020[22] Revenue Breakdown - The company achieved a total revenue of RMB 1,475.25 million, an increase of RMB 980.05 million, representing a year-on-year growth of 197.91%[57] - The pharmaceutical segment generated revenue of RMB 1,056.01 million, with a year-on-year increase of 354.22%[57] - The medical device segment reported revenue of RMB 79.36 million, reflecting a year-on-year growth of 226.51%[57] - The exhibition business generated revenue of RMB 74.79 million, marking a year-on-year increase of 75.78%[57] Market Expansion and Acquisitions - The acquisition of Dicon Pharmaceuticals was completed in October 2020, and in 2021, it achieved a net profit of CNY 125.53 million, fulfilling the performance commitment of CNY 90 million for the second year[29] - The company is expanding into the assisted reproduction sector, holding an 80% voting power in Wuhan Tongji Reproductive Medicine Hospital after a 31% stake change[32] - The company established a joint venture with Shanghai United Imaging Healthcare to provide professional medical diagnostic services[32] Industry Trends - The pharmaceutical manufacturing industry in China saw a revenue increase of 20.1% in 2021, reaching CNY 2.93 trillion, with a profit increase of 77.9% to CNY 627.14 billion[34] - The medical device industry in China is projected to exceed CNY 115 billion in revenue in 2021, driven by policy support for innovation and domestic product replacement[35] - The total retail sales of consumer goods in China reached CNY 4,408.23 billion, representing a year-on-year growth of 12.5% and an 8% increase compared to 2019[37] Product Portfolio and Market Position - The company has 80 pharmaceutical products on the market, focusing on areas such as the digestive system, respiratory system, and anti-infection, with core products including Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules[39] - Rabeprazole Sodium Enteric-coated Tablets ranked third in sales in urban retail pharmacies and fifth in public hospitals in 2020[41] - The company’s absorbable medical membrane product revenue ranked second among all anti-adhesion products in China in 2021[45] Research and Development - The company has a strong R&D team focusing on biomedical materials and pharmaceuticals, with ongoing clinical trials for its innovative drug DDCI-01[54] - The company has received a total of 4 invention patents in 2021, including a biodegradable injection filler and a composite material with tumor suppression effects[80] - The company emphasizes the importance of R&D to enhance product lines and ensure sustainable development[108] Operational Efficiency and Cost Management - Operating costs rose to ¥548,738,320.38, reflecting a 273.19% increase from ¥147,040,062.28 year-over-year[59] - Research and development expenses surged by 253.49% to ¥49,036,765.43, primarily due to increased R&D activities at the newly acquired subsidiary, Dikan Pharmaceutical[59] - The gross profit margin for the overall business was 62.80%, with the pharmaceutical segment achieving a gross margin of 54.43%[62] Governance and Management - The board of directors believes that the company's governance structure generally meets the requirements of the Corporate Governance Code for listed companies[143] - The company has established a set of fair and transparent performance evaluation and incentive mechanisms to promote healthy development[144] - The company has established four specialized committees under the board of directors to enhance governance effectiveness[144] Environmental Responsibility - The company has implemented an environmental monitoring plan, with online monitoring devices installed at wastewater discharge points, ensuring compliance with pollution discharge standards[184] - The company has not faced any administrative penalties due to environmental issues during the reporting period[185] - The company has achieved a continuous two-year recognition as a "Good Environmental Enterprise" in Sichuan Province as of December 31, 2021[188] Challenges and Risks - The company faces significant challenges in its business operations due to the uncertainty brought by the recurring COVID-19 pandemic, which has led to reduced consumer travel and a sharp decline in demand for physical retail[141] - The company recognizes the high-risk nature of R&D in the pharmaceutical industry, particularly in innovative drug development and medical device innovation[139] - The company faces potential pricing risks due to the institutionalization of centralized drug procurement, which may affect revenue and profit margins[138]